Researchers tested the C-Scan system version three in 31 patients at multiple overseas centers. The system detects polyps in patients with unprepared colons.
Here’s what you should know:
1. The device had 76 percent sensitivity and 80 percent specificity.
2. Independent investigators performed confirmatory colonoscopies to crosscheck the results.
3. C-Scan’s newest version included better imaging density, 2D/3D testing and a motility analysis algorithm.
Final results from the trial are expected in the second quarter of 2019.
Check-Cap CEO Alex Ovadia said, “We believe that the encouraging interim results from our ongoing post CE approval study demonstrate a significant progress in the clinical performance of C-Scan compared with previously communicated CE study results for our patient-friendly, and preparation-free colon-cancer screening device.”
Check-Cap will initiate a U.S.-based pilot trial in the fourth quarter of 2018.
More articles on gastroenterology:
ASC supply chain tip of the day: Dedicate a supply chain staff
4 insights on outpatient joint replacement surgery from Dr. Ravi Bashyal
Jim Brown appointed CEO of new HCA Gulf Coast acquisition North Cypress Medical Center — 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
